Eagle Ridge Investment Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Eagle Ridge Investment Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,000	Closed	-$67K	–	167
2019 Q1	$67K	Buy	+2,000	New	+$66.8K	0.01%	159
2017 Q2	–	Sell	-1,167	Closed	-$144K	–	143
2017 Q1	$144K	Buy	+1,167	New	+$153K	0.03%	134
2016 Q2	–	Sell	-1,355	Closed	-$127K	–	133
2016 Q1	$127K	Buy	+1,355	New	+$148K	0.03%	123

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eagle Ridge Investment Management's BLCM Position: Q2 2019 in Review

Eagle Ridge Investment Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 2,000 shares — an estimated $67K sold.

Eagle Ridge Investment Management first reported a position in BLCM in Q1 2016 and held it in 3 quarters. The position peaked at $144K in Q1 2017. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Eagle Ridge Investment Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Eagle Ridge Investment Management sold 2,000 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $67K.
Eagle Ridge Investment Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
Eagle Ridge Investment Management's Bellicum Pharmaceuticals, Inc. position peaked at $144K in Q1 2017.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Eagle Ridge Investment Management's 13F filing for Q2 2019, filed 1 Aug 2019.